News
The Accelerating Therapeutics for Opportunities in Medicine (ATOM) Consortium, an initiative that aims to expedite research and development for new medicines, is making headway.
The group recently released its first product: the ATOM Modeling PipeLine (AMPL, pronounced “ample”), an open-source software package that uses data and machine…
News
A team from the Frederick National Laboratory’s Biopharmaceutical Development Program is developing a new autologous cell therapy line that uses engineered chimeric antigen receptor (CAR) T cells to treat acute myeloid leukemia, a particularly aggressive form of pediatric blood cancer. This foray into cell immunotherapy represents a new avenue of…
News
FREDERICK, Md. -- It has been used in clinical studies on four continents and has been tested in thousands of volunteers. It was produced at the Frederick National Laboratory for Cancer Research over a five-year span to meet increasing clinical demand, and it may play an ongoing role in the future of HIV research.
The investigational product,…
News
FREDERICK, Md. -- The development of a modified poliovirus to treat glioblastoma, a deadly form of brain cancer, is one of the latest examples of the Frederick National Laboratory for Cancer Research stepping in to fill a critical need that few others could meet with developing and manufacturing novel biological agents for early-phase clinical…
News
FREDERICK, Md. -- Drug developers now have access to a shared analytical technology, developed and provided by the Frederick National Laboratory for Cancer Research, that helps fine-tune nanomedicine formulations and overcomes a key hurdle on the path toward Food and Drug Administration approval of effective new therapies and generic versions of…
News
The Nanotechnology Characterization Laboratory (NCL) is collaborating with the Army to develop a candidate vaccine against botulism.
Under a collaboration agreement between the National Cancer Institute and the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), NCL scientists will produce nanoparticle formulations for four…
News
Cancer immunotherapy is a type of treatment in which the body’s own immune system is used to attack and kill cancer cells or keep them from spreading. To date, the immunotherapy agent interleukin-2 (IL-2) has been approved by the U.S. Food and Drug Administration for treating certain types of melanoma and kidney cancer.1
IL-2 therapy, however,…
News
The Frederick National Lab has begun to assist several major pharmaceutical companies in adopting nanotechnologies in early stage drug development, when the approach is most efficient and cost-effective.
For some time, the national lab’s Nanotechnology Characterization Laboratory (NCL) has worked with pharmaceutical companies on reformulating…
News
An investigational brain cancer drug made with disabled polio virus and manufactured at the Frederick National Lab has won breakthrough status from the Food and Drug Administration (FDA) to fast-track its further refinement and clinical testing.
Breakthrough status is designed to speed the development and approval of candidate therapies that…
News
Over the past 12 months, we’ve grown accustomed to seeing Zika in the news. The virus has been linked to thousands of cases of microcephaly in Brazilian babies. Numerous countries, including the United States, have reported Zika-related deaths. And there is no vaccine available at this time.
In the face of what has become a global health…
